Edarbi (azilsartan medoxomil)
- Region
- 🇪🇺 EU
- Active substance
- azilsartan medoxomil
- Company
- Takeda Pharma A/S
- Status
- Authorised
- Therapeutic area
- Hypertension
- CHMP opinion
- Thu 22 Sep 2011
- EU approval
- Wed 07 Dec 2011
- Application
- EMEA/H/C/002293
- ATC
- C09CA09
- Official record
- www.ema.europa.eu
Indication
Edarbi is indicated for the treatment of essential hypertension in adults.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Ipreziv Withdrawn · Takeda Pharma A/S
Follow Edarbi
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.